Depomed Revises Protocol For Gabapentin GR Postherpetic Neuralgia Phase III
After the initial Phase III trial of the extended-release drug failed to show a benefit over placebo in PHN, Depomed gives it another go.
After the initial Phase III trial of the extended-release drug failed to show a benefit over placebo in PHN, Depomed gives it another go.